Dr. Robert Bissonnette and Dr. Kim Papp on Shaping the Future of Clinical Research

Amidst the vibrant atmosphere of the EADV in Berlin, Dr. Bissonnette from Innovaderm Research and Dr. Papp from Probity Medical Research seized a rare moment between presentations to engage in a compelling conversation.

These industry leaders share a common journey—the conception and evolution of their clinical research companies, which began as local endeavors in Canada and blossomed into influential international entities. The pair covered some of the main challenges encountered with conducting vitiligo studies, the intricacies of early phase studies, and offering insights into alopecia areata studies. This exclusive interview will bring to light the historical roots of both organizations and explore the ambitious trajectories envisioned for their respective future.

Listen to the full interview below:

Newsletter

Get notified to have the latest trends and be at the forefront of dermatology clinical research and innovation.

Newsletter subscription resources

*By subscribing to our newsletter, you acknowledge and agree to the terms of our privacy policy.

Blog Article

The Role of Skin barrier Dysfunction in Atopic Dermatitis—The Microbiome

Table of contents Cutaneous Dysbiosis Interplay S. aureus: Its Interaction and Impact on Skin S. aureus and Inflammation Focusing on the microbiome, Staphylococcus aureus (S. aureus) is a widespread bacterium that produces a multilayer biofilm, was shown to colonize the skin and play a critical role in Atopic Dermatitis (AD). Over 70% of people are […]

Blog Article

Enhancing Clinical Performance and Cost Efficiency: The Significance of Protocol Writing in Dermatology Trials

Did you know that protocol amendments are not only common, but also very costly? In fact, as per a recent article by Getz K. et al., 57% of protocols had at least one substantial amendment with an average of 2.3 global amendments for phase 2 and phase 3 studies. The cost to implement one protocol amendment was $141,000 US for a phase 2 study and $535,000 US for a phase 3 study. To avoid unnecessary hassle and expenses, take the time to ensure your protocols are well written and top-notch quality.

Blog Article

How to Write First-Rate Protocols for a Psoriasis Study - Focus: Study Design

The success of any clinical study is dependent upon a sturdy protocol; the overall quality of the study depends on this very document. This is especially true for multicenter studies which involve many investigators and clinical staff. This article will explore the best tips to deliver first-rate protocols in psoriasis to set you apart from the competition. Innovaderm Research Inc specializes in a spectrum of dermatological indications, namely acne vulgaris, atopic dermatitis, and psoriasis.